Osteosarcoma (OS) is the most common primary malignant bone tumor and mainly affects children and adolescents. The OS five-year survival rate remains very low. Thus, novel therapeutic protocols for the treatment of OS are needed. Several approaches targeting deregulated signaling pathways have been proposed. The antitumoral effects of polyphenols, which are naturally occurring compounds with potent antioxidant and anti-inflammatory activity, have been investigated in different tumors. Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers. Therefore, in this study, we evaluated the effect of AT-101, which is the (−) enantiomer and more active form of gossypol, on the growth of human and murine OS cells in vitro and in vivo. Several clinical trials employing AT-101 have been performed, and some clinical trials are ongoing. Our results showed for the first time that AT-101 significantly inhibits OS cell growth in a dose- and time-dependent manner, inducing apoptosis and necrosis and partially activating autophagy. Our results demonstrated that AT-101 inhibits prosurvival signaling pathways depending on Akt, p38 MAPK and JNK. In addition, treatment with AT-101 increases the survival of OS-bearing mice. Overall, these results suggest that AT-101 is a candidate chemo-supportive molecule for the development of novel chemotherapeutic protocols for the treatment of OS.

In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101 / Masuelli, L.; Benvenuto, M.; Izzi, V.; Zago, E.; Mattera, R.; Cerbelli, B.; Potenza, V.; Fazi, S.; Ciuffa, S.; Tresoldi, I.; Lucarelli, E.; Modesti, A.; Bei, R.. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 0167-6997. - 38:3(2020), pp. 675-689. [10.1007/s10637-019-00827-y]

In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101

Masuelli L.
;
Mattera R.;Cerbelli B.;Fazi S.;
2020

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor and mainly affects children and adolescents. The OS five-year survival rate remains very low. Thus, novel therapeutic protocols for the treatment of OS are needed. Several approaches targeting deregulated signaling pathways have been proposed. The antitumoral effects of polyphenols, which are naturally occurring compounds with potent antioxidant and anti-inflammatory activity, have been investigated in different tumors. Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers. Therefore, in this study, we evaluated the effect of AT-101, which is the (−) enantiomer and more active form of gossypol, on the growth of human and murine OS cells in vitro and in vivo. Several clinical trials employing AT-101 have been performed, and some clinical trials are ongoing. Our results showed for the first time that AT-101 significantly inhibits OS cell growth in a dose- and time-dependent manner, inducing apoptosis and necrosis and partially activating autophagy. Our results demonstrated that AT-101 inhibits prosurvival signaling pathways depending on Akt, p38 MAPK and JNK. In addition, treatment with AT-101 increases the survival of OS-bearing mice. Overall, these results suggest that AT-101 is a candidate chemo-supportive molecule for the development of novel chemotherapeutic protocols for the treatment of OS.
2020
apoptosis; AT-101; Bcl-2 inhibitor; osteosarcoma; polyphenol
01 Pubblicazione su rivista::01a Articolo in rivista
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101 / Masuelli, L.; Benvenuto, M.; Izzi, V.; Zago, E.; Mattera, R.; Cerbelli, B.; Potenza, V.; Fazi, S.; Ciuffa, S.; Tresoldi, I.; Lucarelli, E.; Modesti, A.; Bei, R.. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 0167-6997. - 38:3(2020), pp. 675-689. [10.1007/s10637-019-00827-y]
File allegati a questo prodotto
File Dimensione Formato  
Masuelli_Osteosarcoma-growth_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.38 MB
Formato Adobe PDF
2.38 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1401706
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact